pemtumomab

Home
Ligands
pemtumomab

GtoPdb Ligand ID: 8031

Synonyms: HMFG1 | HuHMFG-1 [2]

Comment: Pemtumomab is a monoclonal antibody directed against a specific antigenic epitope (PDTR sequence in the MUC1 tandem repeat [5]) of the mucin 1 (MUC1) expressed by several types of secretory epithelial-derived cancers [4]. MUC1 is a large, heavily glycosylated mucin. It is expressed on the apical surface of the most secretory epithelial cells [1] and an antigenically distinct form of MUC1 is overexpressed in 90% of adenocarcinomas, including cancers of the ovary, breast, and pancreas. This means that antibodies can be targeted to cancerous cells [3,5], sparing normal tissue. Pemtumomab is labelled with the radioisotope yttrium-90.
This antibody does not appear to have an INN (international non-proprietary name), and no peptide sequences are available.

References
1. Gendler SJ. (2001) MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia, 6 (3): 339-53. [PMID:11547902]
2. Krauss J, Courtenay-Luck N, Rybak S. (2006) Biological materials and uses thereof. Patent number: US20060193849. Assignee: Antisoma Plc, National Institutes Of Health. Priority date: 25/02/2005. Publication date: 31/08/2006.
3. Miles DW, Taylor-Papadimitriou J. (1999) Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma. Pharmacol Ther, 82 (1): 97-106. [PMID:10341360]
4. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. (2003) Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother, 26 (1): 47-62. [PMID:12514429]
5. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P. (2001) Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer, 93 (1): 97-106. [PMID:11391628]
6. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G et al.. (2006) Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol, 24 (4): 571-8. [PMID:16446329]

References

1. Gendler SJ. (2001)
MUC1, the renaissance molecule.
J Mammary Gland Biol Neoplasia, 6 (3): 339-53. [PMID:11547902]

2. Krauss J, Courtenay-Luck N, Rybak S. (2006)
Biological materials and uses thereof.
Patent number: US20060193849. Assignee: Antisoma Plc, National Institutes Of Health. Priority date: 25/02/2005. Publication date: 31/08/2006.

3. Miles DW, Taylor-Papadimitriou J. (1999)
Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.
Pharmacol Ther, 82 (1): 97-106. [PMID:10341360]

4. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. (2003)
Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
J Immunother, 26 (1): 47-62. [PMID:12514429]

5. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P. (2001)
Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Int J Cancer, 93 (1): 97-106. [PMID:11391628]

6. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G et al.. (2006)
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
J Clin Oncol, 24 (4): 571-8. [PMID:16446329]